Lobeglitazone

CAS: 607723-33-1

Ref. 3D-FL176227

Produktinformation

• Name: Lobeglitazone
• Synonyme: 5-[[4-[2-[[6-(4-Methoxyphenoxy)-4-pyrimidinyl]methylamino]ethoxy]phenyl]methyl]-2,4-thiazolidinedione, 2,4-Thiazolidinedione, 5-[[4-[2-[[6-(4-methoxyphenoxy)-4-pyrimidinyl]methylamino]ethoxy]phenyl]methyl]-, (5R)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, 2,4-Thiazolidinedione, 5-[[4-[2-[[6-(4-methoxyphenoxy)-4-pyrimidinyl]methylamino]ethoxy]phenyl]methyl]-, 5-[4-[2-[[6-(4-Methoxyphenoxy)pyrimidin-4-yl]methylamino]ethoxy]benzyl]thiazolidine-2,4-dione

Beschreibung

Lobeglitazone is a dipeptidyl peptidase-4 (DPP-4) inhibitor that stimulates glucagon-like peptide-1 receptor (GLP-1R). It is used for the treatment of type 2 diabetes and has been shown to inhibit the proliferation of vascular smooth muscle cells and reduce atherosclerotic lesion size. Lobeglitazone also has an effect on matrix metalloproteinases, which may be related to its ability to inhibit the development of renal fibrosis. Lobeglitazone modulates energy metabolism by increasing insulin sensitivity and reducing insulin levels in blood. This drug also reduces blood pressure and prevents congestive heart failure by lowering blood pressure and improving left ventricular function. The concentration-time curve of lobeglitazone can be monitored with a test that measures serum concentrations every 15 minutes for 24 hours after administration. Lobeglitazone should not be taken by people with metabolic disorders or kidney dysfunction.

• Marke: Biosynth

Chemische Eigenschaften

• Reinheit: Min. 95%